Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
This study aimed to identify the roles of the long non-coding RNA
LINC00114
in colorectal cancer (CRC) development. The expression levels of
LINC00114
and miR-133b in CRC were determined by reverse transcription (RT)-polymerase chain reaction (PCR) and the functions of
LINC00114
in CRC were evaluated
in vitro
and
in vivo
. Methylation-specific PCR assay was performed to detect the miR-133b promoter methylation in CRC cells. Bioinformatics analysis, RNA immunoprecipitation, dual luciferase assay, RNA pull-down, co-immunoprecipitation (IP), and chromatin IP (ChIP) assays were used to elucidate whether
LINC00114
could recruit EZH2/DNMT1 and bind to the miR-133b promoter region, leading to dysregulated methylation and the
depression
of miR-133b. The expression levels of DNA methyltransferases (DNMTs), EZH2, and nucleoporin 214(NUP214) were analyzed by western blotting. Data showed that
LINC00114
was highly expressed, whereas miR-133b was downregulated in the CRC tissues and cells.
In vitro
, silencing
LINC00114
inhibited cell proliferation and impeded cell cycle at the G1/S phase by upregulating miR-133b.
In vivo, LINC00114
knockdown reduced tumor growth. Further analysis showed that the methylation in miR-133b promoter region was increased in the CRC and silencing
LINC00114
increased miR-133b expression through depressing methylation of its promoter region. ChIP-PCR experiments demonstrated that EZH2 and DNMT1 could bind to the miR-133b promoter region and it was abolished by
LINC00114
knockdown. sh-EZH2 reversed the overexpression of DNMTs and CRC cell cycle progression induced by the
LINC00114
upregulation. LINC00114 could regulate the
NUP214 protein
expression by sponging miR-133b. These results demonstrated that
LINC00114
suppressed miR-133b expression via EZH2/DNMT1-mediated methylation of its promoter region, indicating that
LINC00114
might be a potential novel target for CRC diagnosis and treatment.
...
PMID:Long Non-coding RNA
LINC00114
Facilitates Colorectal Cancer Development Through EZH2/DNMT1-Induced miR-133b Suppression. 3192 41